AUTHOR=Zheng Hua-Chuan , Xue Hang , Zhang Cong-Yu , Shi Kai-Hang , Zhang Rui 

TITLE=The clinicopathological significances and related signal pathways of BTG3 mRNA expression in cancers: A bioinformatics analysis

JOURNAL=Frontiers in Genetics

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2022.1006582

DOI=10.3389/fgene.2022.1006582

ISSN=1664-8021

ABSTRACT=<p>B cell transposition gene 3 (BTG3) is reported to be a tumor suppressor and suppresses proliferation and cell cycle progression. This study aims to analyze the clinicopathological and prognostic significances, and signal pathways of <italic>BTG3</italic> mRNA expression in human beings through bioinformatics analysis. We analyzed <italic>BTG3</italic> expression using Oncomine, TCGA (the cancer genome atlas), Xiantao, UALCAN (The University of ALabama at Birmingham Cancer data analysis Portal) and Kaplan-Meier plotter databases. Down-regulated <italic>BTG3</italic> expression was observed in lung and breast cancers, compared with normal tissues (<italic>p</italic> &lt; 0.05), but not for gastric and ovarian cancer (<italic>p</italic> &lt; 0.05). The methylation of <italic>BTG3</italic> was shown to be adversely correlated with its mRNA expression (<italic>p</italic> &lt; 0.05). <italic>BTG3</italic> expression was higher in gastric intestinal-type than diffuse-type carcinomas, G<sub>1</sub> than G<sub>3</sub> carcinomas (<italic>p</italic> &lt; 0.05), in female than male cancer patients, T<sub>1-2</sub> than T<sub>3-4</sub>, and adenocarcinoma than squamous cell carcinoma of lung cancer (<italic>p</italic> &lt; 0.05), in invasive ductal than lobular carcinoma, N<sub>0</sub> than N<sub>1</sub> and N<sub>3</sub>, TNBC (triple-negative breast cancer) than luminal and Her2+, and Her2+ than luminal cancer of breast cancer (<italic>p</italic> &lt; 0.05), and G<sub>3</sub> than G<sub>2</sub> ovarian carcinoma (<italic>p</italic> &lt; 0.05). <italic>BTG3</italic> expression was positively related to the survival rate of gastric and ovarian cancer patients (<italic>p</italic> &lt; 0.05), but not for breast cancer (<italic>p</italic> &lt; 0.05). KEGG and PPI (protein-protein interaction) analysis showed that the <italic>BTG3</italic> was involved in cell cycle and DNA replication, digestion and absorption of fat and protein, spliceosome and ribosome in cancer. <italic>BTG3</italic> expression was positively linked to carcinogenesis, histogenesis, and aggressive behaviors, and was employed to evaluate the prognosis of cancers by regulating cell cycle, metabolism, splicing and translation of RNA.</p>